Jonathan R. Dry

Tempus Labs (United States) — United States

Computer Science · Physical Sciences

30h-index4.0kcitations223works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(47), Melanoma and MAPK Pathways(47), Cancer Genomics and Diagnostics(44), Lung Cancer Treatments and Mutations(39), Protein Degradation and Inhibitors(37)

Publications222 total

Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy
2025Open Access
Pan-Cancer Analysis in the Real-World Setting Uncovers Immunogenomic Drivers of Acquired Resistance Post-Immunotherapy
SSRN Electronic Journal·2025Open Access
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Cancer Cell·2024· 10 citedOpen Access
Long-term breast cancer response to CDK4/6 inhibition defined by TP53-mediated geroconversion
Cancer Cell·2024· 33 citedOpen Access
Author Correction: Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
npj Systems Biology and Applications·2024Open Access
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Supplementary Video S1 from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
npj Systems Biology and Applications·2024· 6 citedOpen Access
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
Nature Communications·2024· 38 citedOpen Access
Abstract 225: Integration of patient-derived tumor organoids and patient clinical multimodal data to investigate the role of organoids in predicting treatment response
Cancer Research·2024
Abstract 5100: Multimodal real world data reveals immunogenomic drivers of acquired and primary resistance to immune checkpoint blockade
Cancer Research·2024
Abstract 902: Explainable AI: Graph machine learning for response prediction and biomarker discovery
Cancer Research·2024· 1 cited
Data from PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models
2024Open Access
page 1 of 12Next →

Frequent Co-authors

Paul D. Smith(11), Julio Sáez-Rodríguez(7), Michael P. Menden(6), Zhongwu Lai(5), Miika Ahdesmäki(5), Robert McEwen(5), Brian Dougherty(5), J. Carl Barrett(5), Darren Hodgson(5), Stephen E. Fawell(5), Mathew J. Garnett(5), Dennis Wang(5), Aleksandra Markovets(4), Matthew J. Sale(4), Simon J. Cook(4), Krishna C. Bulusu(4), Oona Delpuech(4), Kathryn Balmanno(3), Austin Dulak(3), Michael Zinda(3)